Outcome of Transplantation for Myelofibrosis

Karen K. Ballen*, Smriti Shrestha, Kathleen A. Sobocinski, Mei-Jie Zhang, Asad Bashey, Brian J. Bolwell, Francisco Cervantes, Steven M. Devine, Robert Peter Gale, Vikas Gupta, Theresa E. Hahn, William J. Hogan, Nicolaus Kroeger, Mark R. Litzow, David I. Marks, Richard T. Maziarz, Philip L. McCarthy, Gary J. Schiller, Harry C. Schouten, Vivek RoyPeter H. Wiernik, Mary M. Horowitz, Sergio A. Giralt, Mukta Arora

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

168 Citations (Web of Science)

Abstract

Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Biol Blood Marrow Transplant 16: 358-367 (2010)
Original languageEnglish
Pages (from-to)358-367
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 2010

Keywords

  • Myelofibrosis
  • Allogeneic transplantation

Cite this